UBS analyst Andrew Mok downgrades Cano Health (NYSE:CANO) from Neutral to Sell and lowers the price target from $12 to $3.75.
UBS Downgrades Cano Health to Sell, Lowers Price Target to $3.75
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
